Baidu
map

默克与Illumina即将开发新一代肿瘤测序技术

2015-03-12 佚名 生物谷

癌症的诊断的目的一直以来被定义为给患者提供“个性化”和“精准”的医疗服务。但鉴于企业努力追求一种基于基因组数据就能给予最好的个体治疗方案的无所不包的测试,当下的流行词语似乎更倾向于“全面”。 Illumina和默克的生物药公司-默克雪兰诺已经达成合作开发一项全面的新一代肿瘤测序技术,但该协议的财务细节尚未公开。这个协议与去年8月Illumina与阿斯利康,强生旗下Janssen Biote

癌症的诊断的目的一直以来被定义为给患者提供“个性化”和“精准”的医疗服务。但鉴于企业努力追求一种基于基因组数据就能给予最好的个体治疗方案的无所不包的测试,当下的流行词语似乎更倾向于“全面”。

Illumina和默克的生物药公司-默克雪兰诺已经达成合作开发一项全面的新一代肿瘤测序技术,但该协议的财务细节尚未公开。这个协议与去年8月Illumina与阿斯利康,强生旗下Janssen Biotech与赛诺菲的协议类似,但却是独立的。同年9月,赛默飞宣布了与葛兰素史克和辉瑞共同开发基于实体肿瘤的全面癌症基因诊断技术。

默克雪兰诺公司全球业务发展部主管谈到:"我们与Illumima围绕下一代测序技术的合作将使我们建立多年前从未听过的基因组研究,并且将推动多种诊断技术的发展。"

这种新的合作方式将有助于开发和商业化多种支持临床诊断的检测防范。Illumina已经于去年9月成立的组织Actionable Genome Consortium一起工作,并提出了开发下一代对肿瘤基因测序技术的标准。除了Illumina公司,Dana-Farber癌症研究所,Fred Hutchinson癌症研究中心,MD Anderson癌症中心,斯隆凯特琳纪念癌症中心都是Actionable Genome Consortium的创始成员。

Illumina公司的营销总监Richard Klausner博士在一份声明中说到:“这项协议是另一个迈向实现精密医学的承诺”。美国总统奥巴马近日宣布的美国政府的精密医学倡议中,专门列出了把扩大遗传有关的临床试验作为一个对肿瘤进行更好治疗的关键方法。

原始出处:

Stacy Lawrence.Merck Serono, Illumina partner in the latest universal, next-gen, cancer diagnostic deal.FierceMedicalDevice,March 10,2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1723481, encodeId=54381e2348184, content=<a href='/topic/show?id=2a328299202' target=_blank style='color:#2F92EE;'>#肿瘤测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82992, encryptionId=2a328299202, topicName=肿瘤测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac6133458061, createdName=dongjia2021, createdTime=Thu Aug 13 10:39:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928055, encodeId=fd95192805504, content=<a href='/topic/show?id=0b9e9e36fa' target=_blank style='color:#2F92EE;'>#Illumina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9736, encryptionId=0b9e9e36fa, topicName=Illumina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Tue Aug 25 20:39:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273879, encodeId=ec3612e387914, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1723481, encodeId=54381e2348184, content=<a href='/topic/show?id=2a328299202' target=_blank style='color:#2F92EE;'>#肿瘤测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82992, encryptionId=2a328299202, topicName=肿瘤测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac6133458061, createdName=dongjia2021, createdTime=Thu Aug 13 10:39:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928055, encodeId=fd95192805504, content=<a href='/topic/show?id=0b9e9e36fa' target=_blank style='color:#2F92EE;'>#Illumina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9736, encryptionId=0b9e9e36fa, topicName=Illumina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Tue Aug 25 20:39:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273879, encodeId=ec3612e387914, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
    2015-08-25 lxg951
  3. [GetPortalCommentsPageByObjectIdResponse(id=1723481, encodeId=54381e2348184, content=<a href='/topic/show?id=2a328299202' target=_blank style='color:#2F92EE;'>#肿瘤测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82992, encryptionId=2a328299202, topicName=肿瘤测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac6133458061, createdName=dongjia2021, createdTime=Thu Aug 13 10:39:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928055, encodeId=fd95192805504, content=<a href='/topic/show?id=0b9e9e36fa' target=_blank style='color:#2F92EE;'>#Illumina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9736, encryptionId=0b9e9e36fa, topicName=Illumina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Tue Aug 25 20:39:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273879, encodeId=ec3612e387914, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map